FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 621 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Study Finds Accelerated Partial-Breast Radiation Just as Effective as Whole Breast... December 13, 2019 Five Questions with…Fred. April 14, 2022 ESMO Breast Cancer Congress 2022 April 20, 2022 EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment... October 21, 2021 Load more HOT NEWS FDA Approval Likely to Change Initial Treatment for Some People with... EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... Advanced and Metastatic Prostate Cancer Living Guideline
